Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00701181 · ClinicalTrials.gov registry record · Phase 2
Study Evaluating Efficacy and Safety of PF-04523655 Versus Laser in Subjects With Diabetic Macular Edema
A Phase 2 study, sponsored by Quark Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 184
- Enrollment target
NCT00701181 is a Phase 2 study that was terminated before completion, run by Quark Pharmaceuticals. The registered enrollment target is 184 participants.
The verdict
NCT00701181, a Phase 2 study, was terminated before completion, sponsored by Quark Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 184 participants
- Enrollment target
Study Summary
To evaluate the effectiveness of study drug in improving visual acuity compared to laser treatment in the patients with diabetic macular edema
Interventions
- PROCEDURE Laser Treatment
- DRUG PF-04523655 high
- DRUG PF-04523655 middle
- DRUG PF-04523655 low
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 184 participants |
| Start Date | 2008-06 |
| Est. Completion | 2011-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00701181
The ClinicalTrials.gov registry entry for NCT00701181 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 184 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Quark Pharmaceuticals, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Laser Treatment is the first listed.
NCT00701181 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00701181 about?
NCT00701181 is a clinical study titled "Study Evaluating Efficacy and Safety of PF-04523655 Versus Laser in Subjects With Diabetic Macular Edema". To evaluate the effectiveness of study drug in improving visual acuity compared to laser treatment in the patients with diabetic macular edema
What is the current status of trial NCT00701181?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 184 participants. The study started on 2008-06. Estimated completion is 2011-01.
What interventions are being tested in trial NCT00701181?
The interventions under investigation include: Laser Treatment (PROCEDURE), PF-04523655 high (DRUG), PF-04523655 middle (DRUG), PF-04523655 low (DRUG).
Who is sponsoring clinical trial NCT00701181?
This trial is sponsored by Quark Pharmaceuticals, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.